Results 121 to 130 of about 13,380 (189)

Rapid Onset of Clinical Response to Eculizumab in a Single-Center Cohort of Older Patients with Refractory Generalized Myasthenia Gravis. [PDF]

NeuroSci
D'Alvano G, Del Giudice S, D'Anna F, Todisco V, Tessitore A, Bisecco A.   +5 more
europepmc   +1 more source

Eculizumab treatment in the salvage therapy of MOGAD: a case report. [PDF]

Front Immunol
Guo Y, Liu M, Zhang Z.
europepmc   +1 more source

Favorable Outcome With Eculizumab in Hemolytic Uremic Syndrome Presenting With Severe Neurological Complications: A Case Report. [PDF]

Case Rep Nephrol
Zaitoun M, Alanazi A, Kattash T, Wali A, Abdelbagi A, Batati SA, Faqeehi H, Zabali SA.   +7 more
europepmc   +1 more source

Efficacy and safety of crovalimab versus eculizumab in complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria: Chinese subgroup analysis of the phase 3 COMMODORE 2 study. [PDF]

Ann Hematol
Tong H, Lin Z, Yang C, Wang X, Sun J, Xia L, Shi J, Shi D, Zhang Z, Appius A, He G.   +10 more
europepmc   +1 more source

Complement Factor H Mutation-Associated Atypical Haemolytic Uraemic Syndrome Presenting With Dialysis-Dependent Renal Failure: A Case Report. [PDF]

Cureus
Jain A, Mohamed D, Satheesh Nair G, Magriplis M, Yusuf A, Matthews G.   +5 more
europepmc   +1 more source

Complement diagnostics and therapeutics for the pediatric population: early successes and opportunities for further advancement. [PDF]

Front Pharmacol
Whelan RS, Dixon BP.
europepmc   +1 more source

Clinical outcomes and quality of life associated with eculizumab in patients with late-onset myasthenia gravis. [PDF]

Front Immunol
Wang L, Qu M, Rong X, Sun X, Zhao Y, Huang S, Liu M.   +6 more
europepmc   +1 more source